Top

Published in:

01-09-2009 | Breast Oncology

Isolated Tumor Cells in Sentinel Lymph Node and Clinical Implications for Early Breast Cancer

Authors: D. Ziogas, MD, E. G. Lykoudis, MD, G. C. Zografos, MD

Published in: Annals of Surgical Oncology | Issue 9/2009

Excerpt

Clinical decision-making on treatment for breast cancer is based on the highest possible level of evidence.1,2 Sentinel lymph node dissection (SLND) has become standard for assessing axillary nodal status for early breast cancer. Evidence of isolated tumor cells (ITC) or micrometastasis in sentinel lymph nodes (SLN) may influence surgeon’s decision on complete axillary lymph node dissection (CALND). Usually, serial sectioning and immunohistochemical staining are used to evaluate presence of ITC or micrometastasis. Could conventional clinicopathologic factors predict ITC status in SLN in patients with clinical axilla node-negative disease? What would be the clinical implications of this assessment? …

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133–44.PubMedCrossRef

Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21.PubMedCrossRef

Mittendorf EA, Sahin AA, Tucker SL, et al. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008;15:3369–77

Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587–97.PubMedCrossRef

Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26(26):4360–1.PubMedCrossRef

Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–41.PubMedCrossRef

Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. 2005;5(4):737–45.PubMedCrossRef

Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15(1):21–33.PubMedCrossRef

Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.PubMedCrossRef

10.

Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9(3):227–9.CrossRef

11.

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247(4):714–5.PubMedCrossRef

12.

Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956–60.PubMedCrossRef

13.

Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9(9):828–30.PubMedCrossRef

14.

Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197.PubMedCrossRef

15.

Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1636.PubMed

16.

Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9(3):217–21.PubMedCrossRef

17.

Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.PubMedCrossRef

18.

Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.PubMedCrossRef

19.

Roukos DH. Radiation therapy for breast cancer. N Engl J Med. 2009;360(13):1362.PubMedCrossRef

Title: Isolated Tumor Cells in Sentinel Lymph Node and Clinical Implications for Early Breast Cancer
Authors: D. Ziogas, MD
E. G. Lykoudis, MD
G. C. Zografos, MD
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 9/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0455-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Isolated Tumor Cells in Sentinel Lymph Node and Clinical Implications for Early Breast Cancer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2009

Comprehensive Analysis of the Clinical Significance of Inducing Pluripotent Stemness-Related Gene Expression in Colorectal Cancer Cells

Survey of ASCO Members on Management of Sentinel Node Micrometastases in Breast Cancer: Variation in Treatment Recommendations According to Specialty

CRP Genetic Polymorphism Is Associated with Lymph Node Metastasis in Thoracic Esophageal Squamous Cell Cancer

The Impact of Obesity on Outcomes Following Pancreatectomy for Malignancy

Factors Associated with Optimal Cosmetic Results at 36 Months in Patients Treated with Accelerated Partial Breast Irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite® Breast Brachytherapy Registry Trial

High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma